Skip to content

Prevalence of Fibromyalgia in Israel

Prevalence of Fibromyalgia in Israel

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01203865
Enrollment
1200
Registered
2010-09-16
Start date
2010-10-31
Completion date
2012-03-31
Last updated
2011-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Fibromyalgia, Fatigue

Brief summary

The prevalence of fibromyalgia syndrome in the Israeli population is of importance fro planning resource allocation of medical expenditure as well as for identifying demographic and ethnic differences of this unique population compared with other western samples. In the current study the investigators aim at estimating the prevalence of fibromyalgia in this population. For this purpose a two - stage process will be used. First, a population survey will be conducted by telephone, screening for widespread pain and fatigue in the general population. This survey will use the London Fibromyalgia Epidemiology Study Screening Questionnaire. Second, a sample of patients attending the rheumatology clinic will be surveyed with this tool and will be examined in order to determine the actual proportion of patients fulfilling ACR criteria for fibromyalgia. This will enable us to calculate the positive predictive value of the London Fibromyalgia Epidemiology Study Screening Questionnaire in our population and hence to calculate the prevalence of fibromyalgia in the population.

Interventions

None listed

Sponsors

Pfizer
CollaboratorINDUSTRY
Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals over 18 who consent to answer the survey questions

Design outcomes

Primary

MeasureTime frame
Prevalence of fibromyalgia in the Israeli population9 months

Secondary

MeasureTime frame
Demographic data on fibromyalgia patients9 months

Countries

Israel

Contacts

Primary ContactJacob N Ablin, MD
jacobab@tasmc.health.gov.il972-3-6973668

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026